6118 — Austar Lifesciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Austar Lifesciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,015	2,157	1,764	1,500	1,531
Cost of Revenue
Gross Profit	479	489	336	301	293
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,703	2,040	1,794	1,465	1,477
Operating Profit	312	116	-30	35.2	54.2
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	319	120	-34.4	21.2	48.1
Provision for Income Taxes
Net Income After Taxes	273	101	-34.8	13.6	32.9
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	277	87.5	-113	16.1	33.8
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	277	87.5	-113	16.1	33.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.213	0.204	-0.069	0.03	0.058